• Search
  • Advanced Search

Review

January 22, 2025


Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications
Xindi Ke, Shangze Jiang, Qiaoxin Wei, et al.
Clin Mol Hepatol. 2025;31(3):685-705.

The role of the gut microbiome in the development and progression of liver cancer has long been recognized. However, the presence of microbes in tumors that were previously considered sterile...

Review

February 5, 2025


Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications
Huihai Yang, Martina Mang Leng Lei, Longfei Xie, et al.
Clin Mol Hepatol. 2025;31(3):706-729.

Hepatocellular carcinoma (HCC) is a highly lethal cancer due to its aggressive nature and poor prognosis. Adenosine, a key metabolic regulator in the tumor microenvironment (TME), plays a crucial role...

Review

March 26, 2025


Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum
Vishnu Girish, Rakhi Maiwall
Clin Mol Hepatol. 2025;31(3):730-752.

Kidney disease in cirrhosis is now viewed as a continuum encompassing acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD), rather than three different disorders. Contemporary...

Review

April 2, 2025


Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
Hee Yeon Kim, Mary E. Rinella
Clin Mol Hepatol. 2025;31(3):753-770.

Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for...

Review

April 16, 2025


Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
Clin Mol Hepatol. 2025;31(3):771-795.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its relatively advanced form, metabolic dysfunction-associated steatohepatitis (MASH), are becoming increasingly prevalent worldwide, making their prevention and management an urgent global health priority....

Original Article

January 6, 2025


High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, et al.
Clin Mol Hepatol. 2025;31(3):796-809.

Background/Aims: There are no hepatocellular carcinoma (HCC) surveillance recommendations for non-viral chronic liver diseases (CLD), such as metabolic dysfunction-associated steatotic liver disease (MASLD). We explored the Steatosis-Associated Fibrosis Estimator (SAFE)...

Original Article

January 17, 2025


Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, et al.
Clin Mol Hepatol. 2025;31(3):810-822.

Background/Aims: Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral...

Original Article

January 22, 2025


Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis
Jae Yeon Kim, Hyeri Park, Soo Young Park, et al.
Clin Mol Hepatol. 2025;31(3):823-840.

Background/Aims: Epithelial-to-mesenchymal transition (EMT) plays a crucial role in hepatic fibrogenesis and liver repair in chronic liver disease. Our research highlights the antifibrotic potential of placenta-derived mesenchymal stem cells (PD-MSCs)...

Original Article

February 5, 2025


Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome
Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, et al.
Clin Mol Hepatol. 2025;31(3):841-865.

Background/Aims: Hepatitis B virus (HBV) hijacks host cell metabolism, especially host glutamine metabolism, to support its replication. Glutamate dehydrogenase 1 (GDH1), a mitochondrial enzyme crucial for glutamine metabolism, can interact...

Original Article

February 5, 2025


Baveno VI-SSM stratifies the risk of portal hypertensionrelated events in patients with HBV-related cirrhosis
Haiyu Wang, Weihao Liang, Ling Zhou, et al.
Clin Mol Hepatol. 2025;31(3):866-880.

Background/Aims: Cirrhotic patients with liver stiffness measurement (LSM)

Original Article

February 5, 2025


Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study
Bingtian Dong, Ruiling He, Shenghong Ju, et al.
Clin Mol Hepatol. 2025;31(3):881-898.

Background/Aims: A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop...

Original Article

February 5, 2025


Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clin Mol Hepatol. 2025;31(3):899-913.

Background/Aims: The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C,...

Original Article

February 6, 2025


GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma
Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, et al.
Clin Mol Hepatol. 2025;31(3):914-934.

Background/Aims: Hepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC...

Original Article

February 10, 2025


Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, et al.
Clin Mol Hepatol. 2025;31(3):935-959.

Background/Aims: Identifying patients with intrahepatic cholangiocarcinoma (ICC) likely to benefit from immunochemotherapy, the new front-line treatment, remains challenging. We aimed to unveil a novel radiotranscriptomic signature that can facilitate treatment...

Original Article

March 4, 2025


CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in earlystage hepatocellular carcinoma
Yifei Qin, Fei Huo, Zhuan Feng, et al.
Clin Mol Hepatol. 2025;31(3):960-980.

Background/Aims: The identification of factors that lead to CD8+ T cell dysfunction within the tumor microenvironment (TME) holds great promise for the development of innovative immunotherapies. However, the mechanisms underlying...

Original Article

March 11, 2025


Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, et al.
Clin Mol Hepatol. 2025;31(3):981-1002.

Background/Aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in...

Original Article

March 17, 2025


Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
Rui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Clin Mol Hepatol. 2025;31(3):1003-1017.

Background/Aims: Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment. Methods: We analyzed...

Original Article

April 4, 2025


Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
Hye Won Lee, Jae Seung Lee, Mi Na Kim, et al.
Clin Mol Hepatol. 2025;31(3):1018-1031.

Background/Aims: Recently, the Korean Association for the Study of the Liver (KASL) introduced a noninvasive test-based approach that uses the fibrosis-4 (FIB-4) index followed by vibration-controlled transient elastography (VCTE) to...

Original Article

April 11, 2025


MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation
Tiantian Wang, Dean Rao, Chenan Fu, et al.
Clin Mol Hepatol. 2025;31(3):1032-1057.

Background/Aims: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, and abnormal MET expression plays a crucial role in its progression. However, the specific pathogenic mechanisms of MET in HCC have...

Original Article

April 11, 2025


Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, et al.
Clin Mol Hepatol. 2025;31(3):1058-1070.

Background/Aims: Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in...

Original Article

April 21, 2025


HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, et al.
Clin Mol Hepatol. 2025;31(3):1071-1083.

Background/Aims: Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type...

Original Article

April 23, 2025


Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
Xianhua Mao, Xinrong Zhang, Rongtao Lai, et al.
Clin Mol Hepatol. 2025;31(3):1084-1099.

Background/Aims: Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease...
Current Issue
Volume 31(3); Jul 2025
Special Review
2200
Liver disease trends in the Asia-Pacific region for the next 50 years
Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim
Clin Mol Hepatol. 2025;31(3):671-684.   Published online March 4, 2025
View: 1519   Download: 121  Crossref: 1
Review
2153
Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications
Xindi Ke, Shangze Jiang, Qiaoxin Wei, Minghao Sun, Hang Sun, Mingchang Pang, Mei Liu, Lejia Sun, Huayu Yang, Yilei Mao
Clin Mol Hepatol. 2025;31(3):685-705.   Published online January 22, 2025
View: 1775   Download: 195  Crossref: 1
2162
Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications
Huihai Yang, Martina Mang Leng Lei, Longfei Xie, Yinuo Shou, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(3):706-729.   Published online February 5, 2025
View: 1777   Download: 152  Crossref: 1
2222
Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum
Vishnu Girish, Rakhi Maiwall
Clin Mol Hepatol. 2025;31(3):730-752.   Published online March 26, 2025
View: 1249   Download: 153
2227
Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
Hee Yeon Kim, Mary E. Rinella
Clin Mol Hepatol. 2025;31(3):753-770.   Published online April 2, 2025
View: 1670   Download: 185  Crossref: 1
2237
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
Clin Mol Hepatol. 2025;31(3):771-795.   Published online April 16, 2025
View: 1379   Download: 159  Crossref: 1
Original Article
2135
High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao
Clin Mol Hepatol. 2025;31(3):796-809.   Published online January 6, 2025
View: 1885   Download: 200
2149
Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang
Clin Mol Hepatol. 2025;31(3):810-822.   Published online January 17, 2025
View: 2105   Download: 97  Crossref: 1
2152
Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis
Jae Yeon Kim, Hyeri Park, Soo Young Park, Se Ho Kim, Ja Yun Lim, Ki Seog Lee, Si Hyun Bae, Gi Jin Kim
Clin Mol Hepatol. 2025;31(3):823-840.   Published online January 22, 2025
View: 4959   Download: 844
2159
Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome
Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, Xin He, Hui Zhang, Ming Tan, Hai-Bo Yu, Zhen-Zhen Zhang, Ji-Hua Ren, Min-Li Yang, Da-Peng Zhang, Zhi-Hong Li, Juan Chen
Clin Mol Hepatol. 2025;31(3):841-865.   Published online February 5, 2025
View: 1804   Download: 281
2160
Baveno VI-SSM stratifies the risk of portal hypertensionrelated events in patients with HBV-related cirrhosis
Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen
Clin Mol Hepatol. 2025;31(3):866-880.   Published online February 5, 2025
View: 1347   Download: 137
2163
Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study
Bingtian Dong, Ruiling He, Shenghong Ju, Yuping Chen, Ivica Grgurevic, Jianzhong Ma, Ying Guo, Huizhen Fan, Qiang Yan, Chuan Liu, Huixiong Xu, Anita Madir, Kristian Podrug, Jia Wang, Linxue Qian, Zhengzi Geng, Shanghao Liu, Tao Ren, Guo Zhang, Kun Wang, Meiqin Su, Fei Chen, Sumei Ma, Liting Zhang, Zhaowei Tong, Yonghe Zhou, Xin Li, Fanbin He, Hui Huan, Wenjuan Wang, Yunxiao Liang, Juan Tang, Fang Ai, Tingyu Wang, Liyun Zheng, Zhongwei Zhao, Jiansong Ji, Wei Liu, Jiaojiao Xu, Bo Liu, Xuemei Wang, Yao Zhang, Qiong Yan, Hui Liu, Xiaomei Chen, Shuhua Zhang, Yihua Wang, Yang Liu, Li Yin, Yanni Liu, Yanqing Huang, Li Bian, Ping An, Xin Zhang, Shaoting Zhang, Jinhua Shao, Xiangman Zhang, Wei Rao, Chaoxue Zhang, Christoph Frank Dietrich, Won Kim, Xiaolong Qi
Clin Mol Hepatol. 2025;31(3):881-898.   Published online February 5, 2025
View: 2641   Download: 205
2164
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bair, Te-Sheng Chang, Chun-Yen Lin, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzeng-Hue Yang, Cheng-Yuan Peng, Chi-Chieh Yang, Lee-Won Chong, Chien-Wei Huang, Chih-Wen Lin, Cheng-Hsin Chu, Ming-Chang Tsai, Jia-Horng Kao, Chun-Jen Liu, Wan-Long Chuang, Teng-Yu Lee, Ming-Lung Yu, on behalf of TACR investigators
Clin Mol Hepatol. 2025;31(3):899-913.   Published online February 5, 2025
View: 2364   Download: 153
2167
GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma
Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, Moon Gyeong Yoon, Geum Ok Baek, Minji Kang, Se Ha Jang, Won Park, Yunjin Go, Jestlin Tianthing Ng, Suk Woo Nam, Jee-Yeong Jeong, Ji Eun Han, Hyo Jung Cho, Su Bin Lim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Clin Mol Hepatol. 2025;31(3):914-934.   Published online February 6, 2025
View: 3488   Download: 857  Crossref: 2
2172
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, Shu-Ya Cao, Chen-Yu Jiao, Ming Lu, Biao Zhang, Yue Yang, Qing Xu, Xiao-Feng Wu, Ke Wang, Yong-Xiang Xia, Xiang-Cheng Li, Xue-Hao Wang
Clin Mol Hepatol. 2025;31(3):935-959.   Published online February 10, 2025
View: 7601   Download: 353
2202
CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in earlystage hepatocellular carcinoma
Yifei Qin, Fei Huo, Zhuan Feng, Jialu Hou, Yaxin Ding, Quancheng Wang, Yu Gui, Ziwei Yang, Jiali Yang, Gang Zhou, Ling Li, Jianli Jiang, Lingmin Kong, Shijie Wang, Gang Nan, Dingqiao Xu, Xiaohang Xie, Lijuan Wang, Qian He, Ruibin Yang, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu
Clin Mol Hepatol. 2025;31(3):960-980.   Published online March 4, 2025
View: 1773   Download: 291
2207
Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Kohei Hanaoka, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Atsushi Takebe, Takaaki Murase, Keiko Kamei, Takuya Nakai, Ippei Matsumoto, Kazuto Nishio, Masatoshi Kudo
Clin Mol Hepatol. 2025;31(3):981-1002.   Published online March 11, 2025
View: 2073   Download: 221
2212
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Hirokazu Takahashi, Kunihiko Tsuji, Koichi Takaguchi, Pei-Chien Tsai, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Eileen Yoon, Sung Eun Kim, Sang Bong Ahn, Gi-Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng-Hao Tseng, Masatoshi Ishigami, Angela Chau, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrian Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan-Long Chuang, Ramsey Cheung, Chao Wu, Ming-Lung Yu, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(3):1003-1017.   Published online March 17, 2025
View: 2099   Download: 149  Crossref: 1
2230
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Clin Mol Hepatol. 2025;31(3):1018-1031.   Published online April 4, 2025
View: 1151   Download: 124
2234
MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation
Tiantian Wang, Dean Rao, Chenan Fu, Zhoubin Sun, Yiming Luo, Junli Lu, Jie Jin, Han Li, Feimu Fan, Huifang Liang, Wenjie Huang, Limin Xia
Clin Mol Hepatol. 2025;31(3):1032-1057.   Published online April 11, 2025
View: 1742   Download: 244
2235
Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol. 2025;31(3):1058-1070.   Published online April 11, 2025
View: 1748   Download: 100
2240
HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, Ru Bai, Junwei Cheng, Meng Yu, Alexander Liberman, Liping Liu, Nadege Gunn
Clin Mol Hepatol. 2025;31(3):1071-1083.   Published online April 21, 2025
View: 951   Download: 57
2241
Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(3):1084-1099.   Published online April 23, 2025
View: 1621   Download: 166
Snapshot
2165
Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen
Clin Mol Hepatol. 2025;31(3):1100-1102.   Published online February 6, 2025
View: 938   Download: 103
Erratum
Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]
Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang
Clin Mol Hepatol. 2025;31(3):1103-1104.   Published online July 1, 2025
View: 323   Download: 5
Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol. 2025;31(3):1105-1106.   Published online July 1, 2025
View: 321   Download: 7
Letter to the Editor
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
Donghee Kim, Rohit Loomba, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(3):e235-e238.   Published online December 30, 2024
View: 1791   Download: 191  Crossref: 3
What is new in the 2024 Chinese guidelines for fatty liver disease?
Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan
Clin Mol Hepatol. 2025;31(3):e239-e246.   Published online January 21, 2025
View: 905   Download: 68
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai
Clin Mol Hepatol. 2025;31(3):e247-e248.   Published online February 6, 2025
View: 745   Download: 37
2189
Classification of microvascular invasion of hepatocellular carcinoma: Different standards, common goals: Letter to the editor on “Classification of microvascular invasion of hepatocellular carcinoma: Correlation with prognosis and magnetic resonance imaging”
Wei Chen, Yihui Rong, Tianshi Ma, Weiwei Shi, Wei Chen, Hang Jiang
Clin Mol Hepatol. 2025;31(3):e249-e251.   Published online February 18, 2025
View: 801   Download: 61
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou
Clin Mol Hepatol. 2025;31(3):e252-e253.   Published online February 26, 2025
View: 1098   Download: 62
Research Letter
2203
Mendelian randomization does not support the effects of G CSF on decompensated liver disease
Liling Li, Hui Wang, Hong Wang, Jinchang Huang
Clin Mol Hepatol. 2025;31(3):e254-e258.   Published online March 4, 2025
View: 753   Download: 43
2228
Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility
Dongyao Wang, Hongwei Zhang, Yuxiao Tang
Clin Mol Hepatol. 2025;31(3):e259-e262.   Published online April 2, 2025
View: 755   Download: 62  Crossref: 1
Non-infectivity of hepatitis B virus under nucleoside analog therapy revealed through auxiliary partial orthotopic liver transplantation
Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu
Clin Mol Hepatol. 2025;31(3):e263-e267.   Published online May 8, 2025
View: 529   Download: 42
Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(3):e268-e272.   Published online May 8, 2025
View: 531   Download: 34
2262
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease
Pojsakorn Danpanichkul, Donghee Kim, Benjamin Nah, Karn Wijarnpreecha, Suthat Liangpunsakul
Clin Mol Hepatol. 2025;31(3):e273-e276.   Published online May 27, 2025
View: 419   Download: 17
2264
Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023
Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(3):e277-e280.   Published online May 27, 2025
View: 438   Download: 22

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS
FOLLOW US
Twitter
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 2714
TOTAL : 2897216
Close layer